MedTrace Logo

Prophylactic Use of Postpartum Sertraline to Prevent Postpartum Depression

NCT02235064 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2018-03-29

Study results available
· View outcomes & findings →

Summary

The purpose of this project is to assess the effectiveness of preventative antidepressants immediately following delivery on postpartum depression rates in women at high risk due to prior history of depression or postpartum depression.

Conditions

  • Depression, Postpartum

Interventions

DRUG

Sertraline

Capsule containing crushed sertraline 50 mg tablets mixed with identically colored cellulose, with 4 day 25 mg taper

DRUG

Placebo

Capsule containing cellulose powder of same color as experimental arm

Sponsors & Collaborators

  • The Cooper Health System

    lead OTHER

Principal Investigators

  • Richard L Fischer, M.D. · Cooper Health System

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02235064 on ClinicalTrials.gov